Table 2.
Disease characteristics of SSc patients
| SSc patients (N = 105) | |
|---|---|
| Clinical parameters | |
| Disease duration (years), median [IQR] (range) | 12.3 [6.8, 19.3] (0.6, 46.7) |
| Diffuse SSc, n (%) | 23 (21.9%) |
| Clinical manifestation | |
| PAH, n (%) | 5 (4.8%) |
| Pericardial effusion, n (%) | 5 (4.8%) |
| ILD, n (%) | 35 (33.3%) |
| Systemic hypertensiona, n (%) | 32 (32%) |
| Renal crisis, n (%) | 4 (3.8%) |
| Digital ulcersa , n (%) | 14 (14%) |
| mRSSa, median [IQR] (range) | 5 [3, 8] (0, 20) |
| mRSS > 18, n (%) | 1 (1%) |
| GAVE, n (%) | 9 (8.6%) |
| Reflux oesophagitis, n (%) | 59 (56.2%) |
| Oesophageal stricture, n (%) | 9 (8.6%) |
| Oesophageal dysmotility, n (%) | 5 (4.8%) |
| RPa , n (%) | 85 (85%) |
| Calcinosisa , n (%) | 23 (23%) |
| Myositis, n (%) | 2 (1.9%) |
| Synovitisa , n (%) | 11 (11%) |
| Joint contracturea, n (%) | 27 (27%) |
| Pulmonary and cardiac function tests | |
| FVC (% predicted)a, mean (SD) | 93.7 (18.2) |
| FEV1 (% predicted)a, mean (SD) | 89.7 (18.3) |
| DLCO (% predicted)† , b, median [IQR] (range) | 59.5 [48.1, 73.6] (24.6, 116.4) |
| KCO (% predicted)‡ , c, mean (SD) | 64.4 (17.2) |
| 6‐min walk distance (m)d, median [IQR] (range) | 508 [432, 560] (252, 697) |
| LVEF (%)e, median [IQR] (range) | 65 [60, 65] (35, 75) |
| sPAP (mmHg)e , median [IQR] (range) | 31 [28, 39] (21, 108) |
| Clinical laboratory data | |
| ANA +vea , n (%) | 100 (96.2%) |
| ANA anti‐centromere +vea , n (%) | 42 (40.4%) |
| Anti‐topoisomerase Ia , n (%) | 25 (24.3%) |
| Anti‐RNA polymerase III +vea , n (%) | 9 (8.8%) |
| ANCA +vea, n (%) | 27 (26.5%) |
| MPO specificity, n (%) | 3 (2.9%) |
| PR‐3 specificity, n (%) | 3 (2.9%) |
| CRP (mg L−1)b, median [IQR] (range) | 3.5 [1.4, 6] (0.2, 46) |
| ESR (mm h−1)f, median [IQR] (range) | 10 [5, 17] (1, 77) |
| Creatinine (μmol L−1)g, median [IQR] (range) | 65 [54, 76] (36, 149) |
| Treatment, n (%) | |
| Glucocorticoids | 24 (22.9%) |
| PDE5 inhibitor | 5 (4.8%) |
| ERA | 5 (4.8%) |
| Ca2+ channel antagonist | 51 (48.6%) |
| Anticoagulant | 7 (6.7%) |
| Anti‐platelet agent | 19 (18.1%) |
| ACE inhibitor | 11 (10.5%) |
| Angiotensin II receptor blockers | 17 (16.2%) |
| Beta blockers | 5 (4.8%) |
ANA, antinuclear antibodies; ANCA, anti‐neutrophil cytoplasmic antibodies; CRP, C‐reactive protein; DLCO, Hb‐ and gender‐corrected diffusing capacity of the lungs for carbon monoxide; ERA, endothelin receptor antagonist; ESR, erythrocyte sedimentation rate; FEV1, forced expiratory volume in one‐second; FVC, forced vital capacity; GAVE, gastric antral vascular ectasia; ILD, interstitial lung disease; KCO, carbon monoxide transfer coefficient; LV, left ventricular; LVEF, left ventricular ejection fraction; MPO, myeloperoxidase; mRSS, modified Rodnan skin score; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase 5; PR‐3, proteinase 3; RP, Raynaud's phenomenon; RV, right ventricular; Sm, Smith; sPAP, systolic pulmonary arterial pressure; SSc, systemic sclerosis.
a≤ 5 missing values; b10 missing values; c7 missing values; d76 missing values; e28 missing values; f12 missing values; g8 missing values.
Corrected for haemoglobin and gender.
DLCO corrected for lung volume.